


## hCA/VEGFR-2-IN-4

<b>Cat. No.:</b>	HY-155763
<b>CAS No.:</b>	2971782-83-7
<b>Molecular Formula:</b>	C <sub>22</sub> H <sub>23</sub> FN <sub>6</sub> O <sub>5</sub> S
<b>Molecular Weight:</b>	502.52
<b>Target:</b>	VEGFR; Carbonic Anhydrase
<b>Pathway:</b>	Protein Tyrosine Kinase/RTK; Metabolic Enzyme/Protease
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	hCA/VEGFR-2-IN-4 (compound 15b) is an indolinylbenzenesulfonamide and a potential dual inhibitor of cancer-associated hCA IX/XII and VEGFR-2. hCA/VEGFR-2-IN-4 inhibits VEGFR-2 (IC <sub>50</sub> =0.811 μM) and has high binding activity to hCAs, with Ki of 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I), respectively. hCA/VEGFR-2-IN-4 has antiproliferative activity on VEGFR-2-overexpressing breast cancer cells <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	IC <sub>50</sub> : 0.811 μM (VEGFR-2), 3.8 nM (hCA XII), 6.2 nM (hCA IX), 19.8 nM (hCA II), and 35.5 nM (hCA I) <sup>[1]</sup>
<b>In Vivo</b>	hCA/VEGFR-2-IN-4 (compound 15b) MCE has not independently confirmed the accuracy of these methods. They are for reference only.

### REFERENCES

[1]. Saied S, et al. Discovery of indolinone-bearing benzenesulfonamides as new dual carbonic anhydrase and VEGFR-2 inhibitors possessing anticancer and pro-apoptotic properties. *Eur J Med Chem.* 2023 Nov 5;259:115707.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA